Ardian SAS is considering options for Dedalus, including a sale that could value the Italian health-care software provider at more than 3 billion euros ($3.3 billion), according to people familiar with the matter.
The Paris-based private equity firm is working with financial advisers as it explores options to exit its controlling stake in Dedalus, the people said, asking not to be identified discussing confidential information.
Private equity firms and other financial investors have been very active in the health-care sector throughout the Covid-19 pandemic. They were involved in acquisitions of health-care companies valued at $148 billion last year, almost double the previous annual record, data compiled by Bloomberg show.
Read more: BNN Bloomberg
